報價延遲最少15分鐘:2025/07/16 09:14 EDT
盤前時段
|
||||
|
102.5 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
--
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-5.93/-3.03
|
|
企業價值
20.68B
|
| 資產負債 |
|
每股賬面淨值
0.52
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
11.70M
|
|
每股收益
1.48
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/07/16 09:14 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatmentof Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterialhypertension. |
